+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Phosphoinositide 3-Kinase (PI3K) inhibitors Market 2019-2023 - Product Image

Global Phosphoinositide 3-Kinase (PI3K) inhibitors Market 2019-2023

  • ID: 4804066
  • Report
  • July 2019
  • Region: Global
  • 127 Pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bayer AG
  • Gilead Sciences Inc.
  • Novartis AG
  • TG Therapeutics Inc.
  • Verastem Inc.
  • MORE
Global Phosphoinositide 3-Kinase (PI3K) inhibitors Market: About this market

Phosphoinositide 3-kinase (PI3K) inhibitors restricts PI3K enzymes and help in controlling cancer. The phosphoinositide 3-kinase inhibitors market analysis considers sales from chronic lymphocytic leukaemia (CLL), follicular lymphoma (FL), and other indications. This analysis also considers the sales of phosphoinositide 3-kinase inhibitors in Asia, Europe, North America, and ROW. In 2018, the CLL segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high prevalence of CLL and FL and increasing new cases of cancer will play a significant role in the CLL segment to maintain its market position. Also, our global phosphoinositide 3-kinase inhibitors market report also looks at factors such as recent approvals, strategic alliances, and special drug designations. However, low adoption of drugs, clinical trial failures, and stringent regulations may hamper the growth of the phosphoinositide 3-kinase inhibitors industry over the forecast period.

Global Phosphoinositide 3-Kinase (PI3K) inhibitors Market: Overview

Recent approvals

Although many approved therapies are available for various types of blood cancer, the market still witnesses a huge unmet need. Chemotherapies are widely used for the treatment of several types of cancer, including lymphomas. However, chemotherapies have some limitations, which reduces patient adherence toward the treatment. Such factors have fuelled exhaustive research on target therapies such as PI3K inhibitors for the treatment of cancer. Several drugs have been approved, such as copanlisib (ALIQOPA) for the treatment of FL, in September 2017. Thus, recent approvals are expected to fuel the PI3K inhibitors market to grow at a CAGR of about 5% during the forecast period.

Reimbursement programs

The cost of PI3K inhibitors is usually high, owing to the complex manufacturing process. This has also had a negative impact on the PI3K inhibitors market for a long time. Therefore, various government bodies have started patient assistance programs to reduce the cost burden on patients and make these treatments available at an affordable price. Thus, the availability of reimbursement programs is expected to fuel the growth of the PI3K inhibitors market size during the forecast period.

For the detailed list of factors that will drive the global phosphoinositide 3-kinase inhibitors market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of few major players, the global phosphoinositide 3-kinase inhibitors market is concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading phosphoinositide 3-kinase inhibitors manufacturers, that include Bayer AG, Gilead Sciences Inc., Novartis AG, TG Therapeutics Inc., and Verastem Inc.

Also, the phosphoinositide 3-kinase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer AG
  • Gilead Sciences Inc.
  • Novartis AG
  • TG Therapeutics Inc.
  • Verastem Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY APPLICATION
  • Market segmentation by application
  • Comparison by application
  • CLL - Market size and forecast 2018-2023
  • FL - Market size and forecast 2018-2023
  • Other indications - Market size and forecast 2018-2023
  • Market opportunity by application
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Expansion of research indications
  • Reimbursement programs
  • Growing awareness about cancer
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • Gilead Sciences Inc.
  • Novartis AG
  • TG Therapeutics Inc.
  • Verastem Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Application - Market share 2018-2023 (%)
Exhibit 18: Comparison by application
Exhibit 19: CLL - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: CLL - Year-over-year growth 2019-2023 (%)
Exhibit 21: FL - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: FL - Year-over-year growth 2019-2023 (%)
Exhibit 23: Other indications - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: New cases of cancer in US 2015
Exhibit 25: Other indications - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by application
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Proportion of geriatric population in Asia 2007 and 2017
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Drug designations
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Approved drugs with respect to their cancer indications
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: Bayer AG - Vendor overview
Exhibit 54: Bayer AG - Product segments
Exhibit 55: Bayer AG - Organizational developments
Exhibit 56: Bayer AG - Geographic focus
Exhibit 57: Bayer AG - Segment focus
Exhibit 58: Bayer AG - Key offerings
Exhibit 59: Bayer AG - Key customers
Exhibit 60: Gilead Sciences Inc. - Vendor overview
Exhibit 61: Gilead Sciences Inc. - Business segments
Exhibit 62: Gilead Sciences Inc. - Organizational developments
Exhibit 63: Gilead Sciences Inc. - Geographic focus
Exhibit 64: Gilead Sciences Inc. - Key offerings
Exhibit 65: Gilead Sciences Inc. - Key customers
Exhibit 66: Novartis AG - Vendor overview
Exhibit 67: Novartis AG - Business segments
Exhibit 68: Novartis AG - Organizational developments
Exhibit 69: Novartis AG - Geographic focus
Exhibit 70: Novartis AG - Segment focus
Exhibit 71: Novartis AG - Key offerings
Exhibit 72: Novartis AG - Key customers
Exhibit 73: TG Therapeutics Inc. - Vendor overview
Exhibit 74: TG Therapeutics Inc. - Business segments
Exhibit 75: TG Therapeutics Inc. - Organizational developments
Exhibit 76: TG Therapeutics Inc. - Key offerings
Exhibit 77: TG Therapeutics Inc. - Key customers
Exhibit 78: Verastem Inc. - Vendor overview
Exhibit 79: Verastem Inc. - Business segments
Exhibit 80: Verastem Inc. - Organizational developments
Exhibit 81: Verastem Inc. - Key offerings
Exhibit 82: Verastem Inc. - Key customers
Exhibit 83: Validation techniques employed for market sizing
Exhibit 84: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Bayer AG
  • Gilead Sciences Inc.
  • Novartis AG
  • TG Therapeutics Inc.
  • Verastem Inc.
  • MORE
The following companies are recognised as the key players in the global phosphoinositide 3-kinase inhibitors market: Bayer AG, Gilead Sciences Inc., Novartis AG, TG Therapeutics Inc., and Verastem Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the reimbursement programs”

According to the report, one of the major drivers for this market is the recent approvals.

Further, the report states that one of the major factors hindering the growth of this market is the low adoption of drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bayer AG
  • Gilead Sciences Inc.
  • Novartis AG
  • TG Therapeutics Inc.
  • Verastem Inc.
Note: Product cover images may vary from those shown
Adroll
adroll